APUS insider transactions
Apimeds Pharmaceuticals US Inc. (APUS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
APUS insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Apimeds Pharmaceuticals US Inc., latest first. Follow anyone to get their next filing.
- Sungjoon ChaeCo-Chief Executive Officer, since October 2026
- Eric Michael SherbChief Financial Officer, since December 2025
- Vin MenonCo-Chief Executive Officer, since December 2025
- Inscobee Inc.10% owner, since March 2025
- Bennett WeintraubDirector
- Hankil YoonDirector
- Jakap KooDirector+$56.7K
- Carol A O'DonnellDirector
- Elona KoganDirector
- Christopher KimChairman and CMO, Director+$50.4K
- Erik C. EmersonChief Executive Officer, Director
Recent Form 3, 4, and 5 filings for APUS
- SEC Form 3 filed by new insider Chae Sungjoon3 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 3 filed by new insider Sherb Eric Michael3 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 3 filed by new insider Menon Vin3 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Amendment: SEC Form 4 filed by Large owner Inscobee Inc.4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Weintraub Bennett4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Yoon Hankil4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Koo Jakap4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director O'Donnell Carol A4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Kogan Elona4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Kogan Elona4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director O'Donnell Carol A4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Koo Jakap4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Weintraub Bennett4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Chairman and CMO Kim Christopher4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Yoon Hankil4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Emerson Erik C.4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Amendment: Large owner Inscobee Inc. converted options into 115,131 shares, increasing direct ownership by 6% to 2,099,747 units (SEC Form 4)4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Amendment: New insider Inscobee Inc. claimed ownership of 5,619,232 shares (SEC Form 3)3/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Kogan Elona4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Yoon Hankil4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director O'Donnell Carol A4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Chairman and CMO Kim Christopher was granted 250,000 shares, increasing direct ownership by 909% to 277,500 units (SEC Form 4)4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Chief Executive Officer Emerson Erik C. was granted 750,000 shares (SEC Form 4)4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Weintraub Bennett4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- SEC Form 4 filed by Director Koo Jakap4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Chairman and CMO Kim Christopher bought $50,359 worth of shares (27,500 units at $1.83) (SEC Form 4)4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Director Koo Jakap bought $56,715 worth of shares (28,500 units at $1.99), increasing direct ownership by 5% to 643,885 units (SEC Form 4)4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Large owner Inscobee Inc. bought $2,000,000 worth of shares (500,000 units at $4.00) and converted options into 297,133 shares, increasing direct ownership by 37% to 2,028,657 units (SEC Form 4)4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- Amendment: New insider Inscobee Inc. claimed ownership of 5,619,232 shares (SEC Form 3)3/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)